Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II

Slides:

Advertisements

Similar presentations

Evaluation of three 2 nd Line Antiretroviral regimens in Africa (Dakar, Yaounde) « 2 LADY » ANRS project.

Advertisements

Is monitoring for CD4 counts still needed for the management of patients with long- term HIV RNA suppression? Andrew Hill, Liverpool University, UK.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Switch NNRTI to NNRTI  Switch EFV to ETR –CNS toxicity study –Patient’s preference study.

Highlights of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC) September 14-17, 2003; Chicago, Illinois Selected and summarized.

A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.

02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:

A randomized open study comparing the impact of reducing stavudine dose vs. switching to tenofovir on mitochondrial function, metabolic parameters, and.

Switch PI/R to ETR  Etraswitch. Etraswitch Study: Switch PI/r to ETR Continuation of current PI/R + 2 NRTI N = 21 N = 22 ETR 400 mg QD* + 2 NRTI  Design.

Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

DIONE – 24 week efficacy, safety, tolerability and pharmacokinetics of DRV/r QD in treatment-naïve adolescents, 12 to

Switch to ATV- or ATV/r-containing regimen Switch to ATV/r-containing regimen  ATAZIP Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.

Side effects of antiretroviral drugs

FLAMINGO Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14c January 2014.

Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.

Phase 3 Treatment-Naïve and Treatment-Experienced

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP

RAL + MVC + DRV/r + TDF-FTC

EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN

TDF-FTC vs. ABC-3TC, each with Atazanavir + RTV or Efavirenz ACTG 5224s (Bone Effects): Study Design

Switch to PI/r + 3TC vs PI/r monotherapy

TDF-FTC QD + Raltegravir BID TDF-FTC QD + Lopinavir-ritonavir QD

Lopinavir-RTV + TDF-FTC versus Maraviroc + TDF-FTC for PEP MARAVI-PEP: Study Design

Etravirine in Treatment Experienced DUET-2 (TMC125-C216)

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY

Lopinavir-ritonavir mg BID (n = 354)

Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227

Switch to Etravirine from Efavirenz due to CNS Toxicity SSAT-029 STUDY

Switch from EFV plus ABC-3TC to EFV-TDF-FTC ROCKET-1 Trial

Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Dolutegravir + ABC-3TC and CSF HIV-1 RNA Levels ING Study

Etravirine in Treatment Experienced DUET-1 (TMC125-C206)

Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study

Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2

Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial

LPV-RTV versus LPV-RTV + ZDV-3TC in Treatment-Naïve MONARK Trial

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Short Summary German-Austrian ART Guidelines 2017

Switch to DTG + 3TC ASPIRE Study.

Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.

Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals Susanna Naggie, Mark S. Sulkowski Gastroenterology

NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN

Switch to DRV/r + 3TC DUAL Study.

Next Generation Capsid Inhibitor: GS–CA1

Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Switch to DRV/r monotherapy

Comparison of NNRTI vs PI/r

Comparison of PI vs PI ATV vs ATV/r BMS 089

ARV-trial.com Switch to DRV/r + RPV PROBE Study 1.

Comparison of NNRTI vs PI/r

Comparison of NRTI combinations

Switch to ATV/r monotherapy

A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,

Comparison of NRTI combinations

Comparison of NRTI combinations

Presentation transcript:

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Study Design Study Design: ROCKET II Background: Randomized, controlled, 12-week, phase IV trial to assess the effect on lipid profile of switching from abacavir-lamivudine plus lopinavir-ritonavir to tenofovir-emtricitabine plus lopinavir-ritonavir in patients with HIV infection and hyperlipidemia Inclusion Criteria (n = 85) - Age ≥18 - HIV RNA <50 copies/mL for ≥12 weeks - Stable ART with ABC, 3TC, and LPV-RTV ≥24 weeks - Fasting total cholesterol ≥200 mg/dL on two tests ≥4 weeks apart Treatment Arms - TDF-FTC 300-200 mg QD + Lopinavir-ritonavir 200/50 mg as prescribed - ABC-3TC 600-300 mg QD + Lopinavir-ritonavir 200/50 mg as prescribed TDF-FTC + LPV-RTV (n = 42) ABC-3TC + LPV-RTV (n = 43) Source: Behrens G, et al. Antivir Ther. 2012;17:1011-20.

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Results Week 12: Virologic Response (ITT, Missing=Failure) 34/38 37/39 Source: Behrens G, et al. Antivir Ther. 2012;17:1011-20.

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Results Week 12: Analysis of Fasting Lipids Source: Behrens G, et al. Antivir Ther. 2012;17:1011-20.

Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II: Conclusions Conclusions: “Switching to TDF/FTC from ABC/3TC was associated with rapid improvements in fasting lipid parameters and continued virological control in patients receiving LPV/r as the third component of antiretroviral therapy. The effect of these changes on clinical end points remains unclear and would need to be evaluated in a longer-term study.” Source: Behrens G, et al. Antivir Ther. 2012;17:1011-20.